Elias Jabbour

TL;DR: Patients with e14a2 (alone or with coexpressed e13a2) achieved earlier and deeper responses, predicted for optimal European Leukemia Net (ELN) responses (at 3, 6, and 12 months) and predicted for longer event-free and transformation-free survival.

TL;DR: Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy.

TL;DR: Four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromosome-like (Ph-like) ALL result in truncation of the cytoplasmic tail of EPOR at residues similar to those mutated in primary familial congenital polycythemia, with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues.

TL;DR: The clinical efficacy of crenolanib in relapsed/refractory AML pts with activating FLT3 mutations was evaluated and it was found that achieving marrow response (CRi and MLFS) had superior EFS, with a trend toward superior OS for the marrow responders.

TL;DR: Results from salvage therapy in adult patients with acute lymphocytic leukemia are wide‐ranging and depend on several disease and patient characteristics and multivariate analyses of patient and disease characteristics are conducted.